MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/07/23
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial ResultsGlobeNewsWire • 02/23/23
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD ConferenceGlobeNewsWire • 02/22/23
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023GlobeNewsWire • 02/16/23
Mannkind Corporation to Participate in the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/10/23
MannKind Corporation to Participate in the Lytham Partners Investor Select ConferenceGlobeNewsWire • 01/24/23
MannKind's Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung DiseaseGlobeNewsWire • 01/23/23
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/23
After Golden Cross, MannKind (MNKD)'s Technical Outlook is BrightZacks Investment Research • 12/06/22
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022GlobeNewsWire • 11/01/22
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor ConferenceGlobeNewsWire • 09/21/22